Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho Sells 5,742 Shares of Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho sold 5,742 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $36.83, for a total transaction of $211,477.86. Following the completion of the transaction, the general counsel now owns 189,295 shares in the company, valued at approximately $6,971,734.85. This trade represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Junlin Ho also recently made the following trade(s):

• On Thursday, January 16th, Junlin Ho sold 9,039 shares of Scholar Rock stock. The shares were sold at an average price of $44.20, for a total transaction of $399,523.80.

Scholar Rock Trading Down 3.7 %

Shares of SRRK opened at $37.70 on Friday. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The company’s fifty day moving average is $41.81 and its two-hundred day moving average is $28.37. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63.

Analyst Ratings Changes

Several analysts have commented on the stock. Truist Financial lifted their target price on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. HC Wainwright lifted their price objective on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Finally, Wedbush reiterated an “outperform” rating and issued a $47.00 target price on shares of Scholar Rock in a research note on Wednesday, January 29th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Scholar Rock currently has a consensus rating of “Buy” and an average price target of $40.43.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after buying an additional 269 shares during the period. Global Retirement Partners LLC raised its position in Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after purchasing an additional 766 shares during the period. Nisa Investment Advisors LLC lifted its stake in shares of Scholar Rock by 1,321.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after purchasing an additional 1,031 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Scholar Rock in the fourth quarter worth about $85,000. Finally, Amalgamated Bank grew its stake in shares of Scholar Rock by 30.6% in the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after buying an additional 620 shares in the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.